BASF used the International Federation of Societies of Cosmetic Chemists' 2026 Congress in Perth, Australia, to disclose its program in collagen hybridizing peptides (CHPs) — a class of bioactive peptides borrowed from biomedical research that recognize and bind to damaged collagen structures while enhancing the fibroblast–matrix interactions critical for skin regeneration.

The disclosure is the strongest signal yet that collagen-targeting peptide technology, until now confined largely to biomedical and diagnostic research, is moving into the cosmetic active ingredient pipeline. According to BASF, the lead CHP candidate has now cleared a clinical study, the highest evidence class presented at the congress for this mechanism.

What the clinical study showed

The BASF research team demonstrated four effects in the clinical study: the lead CHP candidate selectively targets altered collagen, stimulates procollagen I production, supports tissue repair processes, and significantly reduces the presence of damaged collagen. Procollagen I is the soluble precursor of type I collagen, the dominant structural protein in dermal extracellular matrix and the standard biomarker for de novo collagen synthesis in cosmeceutical and pharmaceutical testing.

The company frames the mechanism as one of targeted repair rather than broad stimulation. Because CHPs bind preferentially to damaged collagen structures, the peptide homes in on compromised matrix rather than intact tissue — a targeting logic the company says improves cellular communication and addresses visible signs of skin aging through collagen repair.

BASF credits AI-driven molecular modeling as an enabling tool in the program. The computational work supported the design and optimization of the peptide candidates, which the company positions as an example of "intelligent peptide technologies" in skin care. Manufacturer claims and trial data sit side by side in the announcement: the clinical endpoints — procollagen I stimulation, reduced damaged collagen — come from the study, while the broader positioning around AI-designed peptides remains corporate framing. BASF did not disclose the peptide sequence, concentration, vehicle, sample size, or study duration in the congress materials.

Stanford collaboration on bio-based polysaccharide films

In a second presentation in Perth, BASF reported joint research with Stanford University on how bio-based polysaccharides form functional films on the skin and influence hydration, barrier properties, and formulation performance.

The Stanford-BASF team investigated the mechanisms behind film formation: molecular entanglement and crystallization of biopolymers, and how those structural phenomena regulate water transport within the stratum corneum. That is a formulation-science question with direct clinical relevance — occlusive and humectant film behavior governs transepidermal water loss, moisture retention, and the sensory performance of moisturizers.

The results showed that bio-based polysaccharide additives improve hydration retention, facilitate emollient penetration, and reduce drying-induced stress while maintaining optimal skin barrier function. For formulators, the finding that film-forming biopolymers can enhance emollient penetration — rather than simply trapping moisture — opens a route to multifunctional sustainable rheology and film-forming agents. The findings, BASF says, provide new insights for developing sustainable, high-performance moisturizing formulations that support long-term skin health.

Coconut water as an extraction solvent

A third data set, presented on the podium by Nicole Lv, technical key account manager at BASF Beauty Care Solutions, APAC, addressed ingredient manufacturing rather than skin biology. Lv introduced a novel extraction approach that uses naturally derived solvents — specifically plant waters, with coconut water as the lead example — in place of conventional extraction solvents.

The study showed that coconut water significantly increased polyphenol content across various botanical sources and enriched specific extracts with defined compound classes: rose extracts gained flavonol glycosides, and citrus extracts gained flavanone glycosides. Those are measurable chemistry endpoints, not marketing descriptors, and they position coconut water as both a sustainability play and an efficacy play — the solvent itself boosted the concentration of the marker actives the extracts are valued for.

Beyond extraction chemistry, extracts obtained through coconut water extraction demonstrated benefits related to epidermal cohesion and barrier resilience, suggesting the bio-inspired process may deliver functional skin benefits as well as greener provenance. Lv's findings, BASF says, open opportunities to unlock more potent cosmetic ingredients through bio-inspired extraction technologies.

What it means for dermatology practice

None of the three programs has produced a named commercial ingredient with published dosing and clinical dossier at this stage. But the CHP platform in particular bears watching: collagen hybridizing peptides have an established mechanistic pedigree in biomedical research, and a clinical demonstration of selective binding to damaged collagen with procollagen I upregulation — even without disclosed effect sizes — marks the mechanism's arrival in the cosmetic active space. Dermatologists fielding patient questions about "collagen-repair" cosmeceuticals will increasingly encounter CHP-derived claims, and the evidentiary bar for those claims will depend on whether BASF publishes the study details its congress abstract omitted.

The Stanford collaboration, meanwhile, adds mechanistic depth to a category — bio-based polysaccharide moisturizers — where formulation claims often outrun published science, and the coconut water extraction work signals a broader industry shift toward greener solvent systems.

BASF has not announced commercialization timelines for the CHP candidate, but the scale of the Perth presentation — a clinical-stage peptide program, a university film-formation collaboration, and a green chemistry extraction platform across one congress — indicates the company intends to bring each line to the ingredients market in the coming development cycles.